---
title: "Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300482.SZ.md"
symbol: "300482.SZ"
name: "Guangzhou Wondfo Biotech Co.,Ltd"
industry: "Health Care Equipment"
datetime: "2026-05-21T09:10:55.441Z"
locales:
  - [en](https://longbridge.com/en/quote/300482.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300482.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300482.SZ.md)
---

# Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)

## Company Overview

Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; automatic blood gas biochemical analyzer and blood gas analyzer; molecular diagnostics platform; fully automated pathology straining system; and fully automatic HbAlc analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP campaign, international public health solutions, POCT lab, and COVID-19 total solution.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | CN Market |
| Website | [www.wondfo.com.cn](https://www.wondfo.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: D (0.65)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 60 / 64 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -37.81% |  |
| Net Profit YoY | -131.51% |  |
| P/B Ratio | 1.57 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8460739435.00 |  |
| Revenue | 1864705427.47 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -2.98% | D |
| Profit Margin | -8.98% | D |
| Gross Margin | 63.24% | A |
| Revenue YoY | -37.81% | E |
| Net Profit YoY | -131.51% | E |
| Total Assets YoY | -6.24% | D |
| Net Assets YoY | -4.49% | D |
| Cash Flow Margin | -494.75% | E |
| OCF YoY | -37.81% | E |
| Turnover | 0.27 | D |
| Gearing Ratio | 17.17% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Guangzhou Wondfo Biotech Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-37.81%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-131.51%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.57",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8460739435.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1864705427.47",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-2.98%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-8.98%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "63.24%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-37.81%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-131.51%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.24%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-4.49%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-494.75%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-37.81%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.27",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "17.17%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -50.53 | 58/64 | 37.31 | 32.08 | 21.76 |
| PB | 1.57 | 9/64 | 1.93 | 1.82 | 1.70 |
| PS (TTM) | 4.54 | 17/64 | 3.93 | 3.68 | 3.46 |
| Dividend Yield | 2.27% | - | 2.15% | 1.94% | 1.85% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | APT (688617.SH) | A | B | B | A | B | A |
| 02 | United Imaging Healthcare (688271.SH) | B | A | C | B | B | B |
| 03 | iRay (688301.SH) | B | A | D | C | A | B |
| 04 | YUYUE MEDICAL (002223.SZ) | B | C | C | A | C | B |
| 05 | Insight Lifetech (688712.SH) | B | A | E | A | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-27T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 80% |
| Overweight | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 17.92 |
| Highest Target | 29.00 |
| Lowest Target | 24.58 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300482.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300482.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300482.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300482.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**